Company Overview of Daiichi-Sankyo Pharma Development, Inc
Daiichi-Sankyo Pharma Development, Inc engages in the development of drugs and therapeutic agents for Cardiovascular, Diabetes, Infection, Immunology, Oncology, and Bone and joint diseases. The company also provides research and development services. The major products of the company includes pactimibe and ARQ 197. The company is based in Edison, New Jersey. Daiichi-Sankyo Pharma Development, Inc operates as a subsidiary of Daiichi Sankyo, Inc.
399 Thornall Street
Edison, NJ 08837
Key Executives for Daiichi-Sankyo Pharma Development, Inc
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
To contact Daiichi-Sankyo Pharma Development, Inc, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.